Key result
Streptokinase therapy for acute MI can trigger delayed serum sickness regardless of dose or route.
Why the study?
Serum sickness after streptokinase therapy in acute myocardial infarction may occur independently of dose or administration route and can complicate treatment.
Serum sickness can occur as a complication of streptokinase therapy for acute myocardial infarction, regardless of dose or route of administration.
Answers are grounded in this paper and cite their sources.
Serum sickness may occur after streptokinase independent of dose or route; leaves open incidence and relevance for intracoronary use.
A case of delayed serum sickness with transient renal impairment is described in a patient who received early high dose intravenous streptokinase following acute myocardial infarction. Review of the literature suggests that serum sickness after streptokinase may occur independently of the dose or route of administration, and could potentially complicate intracoronary streptokinase therapy.
No takes yet. Share an insight, caveat, or question.
Alexopoulos et al. (1984) studied this question. Streptokinase therapy for acute myocardial infarction can be complicated by delayed serum sickness, which may occur independently of the dose or route of administration.
Synapse has enriched 10 related papers. Consider them for comparative context: